Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes

被引:61
作者
Straight, AM
Oakley, K
Moores, R
Bauer, AJ
Patel, A
Tuttle, RM
Jimeno, J
Francis, GL
机构
[1] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA
[2] Walter Reed Army Med Ctr, Dept Pediat, Washington, DC 20307 USA
[3] Mem Sloan Kettering Canc Ctr, Endocrinol Sect, New York, NY 10021 USA
[4] PharmaMar SAU RD Colmenar Viejo, Madrid, Spain
关键词
thyroid cancer; aplidin; angiogenesis;
D O I
10.1007/s00280-005-0014-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Anaplastic thyroid cancer (ATC) is one of the most aggressive and highly lethal human cancers. Median survival after diagnosis is 4-6 months despite available radiotherapy and chemotherapy. Additional treatments are needed for ATC. Vascular endothelial growth factor (VEGF) is a potent angiogenic stimulus, which is expressed by ATC. Previously, anti-VEGF antibody was used to block VEGF-dependent angiogenesis in ATC xenografts. This treatment induced partial (56%) but not complete tumor regression. Aplidin (APLD) is a marine derived antitumor agent currently in phase II clinical studies. Multiple activities of this compound have been described which likely contribute to its antiproliferative effect. Notably, APLD has been shown to have antiangiogenic properties which include: inhibition of VEGF secretion, reduction in the synthesis of the VEGF receptor (FLT-1), and blockade of matrix metalloproteinase production by endothelial cells. We hypothesized that Aplidin, with its broad spectrum of action and antiangiogenic properties, would be a potentially effective drug against ATC. Methods: Thirty BALB/c nu/nu mice were injected with ATC cells (ARO-81, 1X10(6)) and allowed to implant for 3 weeks. Animals were randomized to receive daily intraperitoneal injections of vehicle, low dose (0.5 mg/kg/day), or high dose (1.0 mg/kg/day) APLD. After 3 days, the animals were killed and the tumors were removed, weighed, and divided for RNA and protein analyses. Results: APLD significantly reduced ATC xenograft growth (low dose, 20% reduction, P=0.01; high dose, 40% reduction, P<0.001). This was associated with increased levels of apoptosis related proteins polyadenosylribose polymerase 85 (PARP-85, 75% increase, P=0.024) and caspase 8 (greater than fivefold increase, P=0.03). APLD treatment was further associated with lost or reduced expression of several genes that support angiogenesis to include: VEGF, hypoxia inducible factor 1(HIF-1), transforming growth factor-beta (TGF beta), TGF beta receptor 2 (TGF beta R2), melanoma growth stimulating factor 1 (GRO1), cadherin, and vasostatin. Conclusions: This data supports the hypothesis that APLD may be an effective adjunctive therapy against ATC. The demonstrated molecular impact against angiogenic related genes specifically supports future strategies combining APLD with VEGF interacting agents.
引用
收藏
页码:7 / 14
页数:8
相关论文
共 51 条
[11]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[12]   Analysis of aplidine (dehydrodidemnin B), a new marine-derived depsipeptide, in rat biological fluids by liquid chromatography-tandem mass spectrometry [J].
Celli, N ;
Gallardo, AM ;
Rossi, C ;
Zucchetti, M ;
D'Incalci, M ;
Rotilio, D .
JOURNAL OF CHROMATOGRAPHY B, 1999, 731 (02) :335-343
[13]  
CRAMPTON SL, 1984, CANCER RES, V44, P1796
[14]  
CREWS CM, 1994, J BIOL CHEM, V269, P15411
[15]   In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells [J].
Depenbrock, H ;
Peter, R ;
Faircloth, GT ;
Manzanares, I ;
Jimeno, J ;
Hanauske, AR .
BRITISH JOURNAL OF CANCER, 1998, 78 (06) :739-744
[16]  
Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97
[17]   Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors [J].
Dziba, JM ;
Marcinek, R ;
Venkataraman, G ;
Robinson, JA ;
Ain, KB .
THYROID, 2002, 12 (12) :1063-1070
[18]   Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine [J].
Erba, E ;
Bassano, L ;
Di Liberti, G ;
Muradore, I ;
Chiorino, G ;
Ubezio, P ;
Vignati, S ;
Codegoni, A ;
Desiderio, MA ;
Faircloth, G ;
Jimeno, J ;
D'Incalci, M .
BRITISH JOURNAL OF CANCER, 2002, 86 (09) :1510-1517
[19]   The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults [J].
Fenton, C ;
Patel, A ;
Dinauer, C ;
Robie, DK ;
Tuttle, RM ;
Francis, GL .
THYROID, 2000, 10 (04) :349-357
[20]   Chromogranin A fragments modulate cell adhesion - Identification and characterization of a pro-adhesive domain [J].
Gasparri, A ;
Sidoli, A ;
Sanchez, LP ;
Longhi, R ;
Siccardi, AG ;
Marchisio, PC ;
Corti, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (33) :20835-20843